Preirradiation chemotherapy for advanced head and neck carcinomas

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Chemotherapy and Radiotherapy

Background:

• Locally advanced squamous cell carcinoma of the head and neck presents a significant treatment challenge.
• The integration of chemotherapy prior to radiotherapy (RT) is explored to improve treatment outcomes.

Purpose of the Study:

• To evaluate the efficacy and toxicity of neoadjuvant chemotherapy (cisplatin, bleomycin sulfate, vincristine sulfate) followed by radiotherapy (RT) in patients with locally advanced head and neck cancer.
• To compare outcomes of combined-modality therapy with RT alone in terms of response rate, toxicity, and survival.

Main Methods:

• A cohort of 26 patients received combination chemotherapy (cisplatin, bleomycin sulfate, vincristine sulfate) before RT.
• A concurrent control group of 20 patients received high-dose RT alone.
• Outcomes assessed included response rates, toxicity (hematologic, renal), weight loss, normal tissue reactions, complete tumor resolution, and recurrence-free survival.

Main Results:

• The neoadjuvant chemotherapy regimen achieved a 65% major response rate (all partial responses).
• Minimal additional toxicity was observed; only two patients had significant hematologic effects, and no severe renal toxicity occurred.
• Complete tumor resolution rates were similar (45% for RT alone vs. 42% for combined therapy), as was recurrence-free survival.

Conclusions:

• Pre-irradiation chemotherapy in this regimen, despite a high initial response rate and acceptable toxicity, did not significantly enhance complete tumor response or long-term recurrence-free survival in locally advanced head and neck squamous cell carcinoma.
• The findings suggest that this specific neoadjuvant chemotherapy strategy does not offer a major benefit over standard radiotherapy alone for this patient population.